| P2093 | author name string | Fabio Cominelli | |
| | Theresa T Pizarro | |
| | Luca Pastorelli | |
| | Maurizio Vecchi | |
| P2860 | cites work | Natalizumab Induction and Maintenance Therapy for Crohn's Disease | Q22250890 |
| | Probiotics for induction of remission in ulcerative colitis | Q24242963 |
| | Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis | Q24243219 |
| | Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis | Q24246085 |
| | PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL | Q24311741 |
| | Reduced Paneth cell alpha-defensins in ileal Crohn's disease | Q24538724 |
| | The risk of colorectal cancer in ulcerative colitis: a meta-analysis | Q24669747 |
| | Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine | Q24685403 |
| | Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis | Q24685584 |
| | Trichuris suis therapy in Crohn's disease | Q24685735 |
| | Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine | Q24685766 |
| | A pilot trial of Saccharomyces boulardii in ulcerative colitis | Q28184581 |
| | Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial | Q28244734 |
| | Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease | Q28255557 |
| | Cell-based drug delivery | Q28257039 |
| | Infliximab for induction and maintenance therapy for ulcerative colitis | Q28285876 |
| | A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial | Q57012796 |
| | Erythrocytes-Mediated Delivery of Dexamethasone in Steroid-Dependent IBD Patients-A Pilot Uncontrolled Study | Q58193662 |
| | Risk factors for colorectal cancer in patients with ulcerative colitis: A case-control study | Q58834128 |
| | Epithelial NEMO links innate immunity to chronic intestinal inflammation | Q59091394 |
| | VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis | Q59120549 |
| | Increased intestinal permeability and NOD2 variants in familial and sporadic Crohn's disease | Q62572598 |
| | Course of ulcerative colitis: analysis of changes in disease activity over years | Q72036054 |
| | Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis | Q73837821 |
| | The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study | Q74315857 |
| | Erythrocyte engineering for drug delivery and targeting | Q74845391 |
| | A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin | Q77868324 |
| | Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis | Q79333602 |
| | Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis | Q79596195 |
| | Once-daily, high-concentration MMX mesalamine in active ulcerative colitis | Q79621238 |
| | Rosiglitazone, a PPARgamma ligand, modulates signal transduction pathways during the development of acute TNBS-induced colitis in rats | Q79895160 |
| | Nonadherence in inflammatory bowel disease: results of factor analysis | Q80407754 |
| | Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody | Q80417031 |
| | Phosphatidylcholine and lysophosphatidylcholine in intestinal mucus of ulcerative colitis patients. A quantitative approach by nanoElectrospray-tandem mass spectrometry | Q80928564 |
| | Risk factors for non-adherence to medication in inflammatory bowel disease patients | Q81468420 |
| | Phosphatidylcholine for steroid-refractory chronic ulcerative colitis: a randomized trial | Q81535344 |
| | Helminths as governors of immune-mediated inflammation | Q28289350 |
| | Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial | Q30440147 |
| | Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. | Q30581062 |
| | Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial | Q33872486 |
| | Cyclosporine in severe ulcerative colitis refractory to steroid therapy | Q34060783 |
| | Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study | Q34100121 |
| | PPAR gamma: an essential role in metabolic control | Q34267993 |
| | CTLA4Ig: a novel inhibitor of costimulation | Q34330606 |
| | Low dose steroids and clinical relapse in Crohn's disease: a controlled trial | Q34474565 |
| | A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease | Q34529230 |
| | Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study | Q34601527 |
| | Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis | Q34686103 |
| | A new orally bioavailable synthetic androstene inhibits collagen-induced arthritis in the mouse: androstene hormones as regulators of regulatory T cells | Q34697252 |
| | Review article: diagnosis, monitoring and treatment of distal colitis | Q35144997 |
| | Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease | Q35594747 |
| | A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis | Q35596970 |
| | PPARgamma as a new therapeutic target in inflammatory bowel diseases | Q35768913 |
| | Mesalamine derivatives in the treatment of Crohn's disease | Q35792320 |
| | How effective are the usual treatments for ulcerative colitis? | Q35826343 |
| | Intravenous cyclosporine for the treatment of severe steroid refractory ulcerative colitis: what is the cost? | Q36188830 |
| | Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma | Q36403491 |
| | American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease | Q36418617 |
| | Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis | Q36474506 |
| | TNFalpha blockade in human diseases: an overview of efficacy and safety | Q36536861 |
| | Review article: thiopurines in inflammatory bowel disease | Q36570796 |
| | Probiotics in experimental and human inflammatory bowel disease: discussion points | Q36720509 |
| | Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment? | Q36864836 |
| | Heparin, low molecular weight heparin, and derivatives in thrombosis, angiogenesis, and inflammation: emerging links | Q36880833 |
| | Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis | Q36930800 |
| | Quality of life of patients with ulcerative colitis: past, present, and future | Q36987080 |
| | Role of the intestinal barrier in inflammatory bowel disease | Q37058869 |
| | A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis | Q37169674 |
| | Mechanisms of probiotic action: Implications for therapeutic applications in inflammatory bowel diseases | Q37214848 |
| | Molecular analysis of the intestinal microflora in IBD. | Q37349762 |
| | TGF-beta1 and Smad7 in the regulation of IBD. | Q37349788 |
| | The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial | Q37374964 |
| | Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors | Q37404890 |
| | Pathogenesis of and unifying hypothesis for idiopathic pouchitis | Q37405919 |
| | Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. | Q39315460 |
| | NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. | Q40017434 |
| | The intestinal anti-inflammatory activity of UR-12746S on reactivated experimental colitis is mediated through downregulation of cytokine production. | Q40608087 |
| | Colorectal cancer prevention in ulcerative colitis: a case-control study. | Q41716716 |
| | PPARgamma in monocytes: less pain, any gain? | Q41755827 |
| | Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats. | Q42477845 |
| | A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis | Q42661339 |
| | Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease | Q42684792 |
| | Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation | Q42758588 |
| | Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies | Q43072226 |
| | Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis | Q43867015 |
| | Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort | Q44024340 |
| | Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial | Q44151825 |
| | Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. | Q44299613 |
| | Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column | Q44304714 |
| | The effect of 5-aminosalicylic acid-containing drugs on sulfide production by sulfate-reducing and amino acid-fermenting bacteria | Q44375240 |
| | Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial | Q44387824 |
| | The use of thiopurines for the treatment of inflammatory bowel diseases in clinical practice. | Q44408412 |
| | Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. | Q44488900 |
| | Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis | Q44524238 |
| | Long-term results of low-dose intravenous ciclosporin for acute severe ulcerative colitis | Q44535154 |
| | Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. | Q44758742 |
| | A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis | Q44833501 |
| | Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis | Q45009367 |
| | Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis | Q46143449 |
| | Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine: a single-blind randomized controlled trial | Q46368289 |
| | A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. | Q46469247 |
| | Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. | Q46531976 |
| | Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin | Q46549276 |
| | Efficacy of intracolonic administration of low-molecular-weight heparin CB-01-05, compared to other low-molecular-weight heparins and unfractionated heparin, in experimentally induced colitis in rat. | Q46605939 |
| | TARGIT technology: coated starch capsules for site-specific drug delivery into the lower gastrointestinal tract | Q46810701 |
| | Oral, colonic-release low-molecular-weight heparin: an initial open study of Parnaparin-MMX for the treatment of mild-to-moderate left-sided ulcerative colitis. | Q47220932 |
| | Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. | Q47827799 |
| | Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study | Q48677169 |
| | Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. | Q49073992 |
| | Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. | Q50483095 |
| | Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. | Q51447024 |
| | Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting. | Q51818669 |
| | Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. | Q51872306 |
| | Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways. | Q53482470 |
| | Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. | Q54327204 |
| | Probiotic E. coli treatment mediates antimicrobial human beta-defensin synthesis and fecal excretion in humans. | Q54411332 |
| | Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells. | Q54776568 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ulcerative colitis | Q1477 |
| P304 | page(s) | 505-521 | |
| P577 | publication date | 2009-09-01 | |
| P1433 | published in | Expert Opinion on Emerging Drugs | Q5421207 |
| P1476 | title | Emerging drugs for the treatment of ulcerative colitis | |
| P478 | volume | 14 | |